Document is current

Article History

Received: 14 July 2020

Accepted: 11 May 2021

First Online: 9 June 2021

Competing interests

: V.K.K. has an ownership interest in and is a member of the scientific advisory board for Tizona Therapeutics, Bicara Therapeutics, Compass Therapeutics, Larkspur Biosciences and Trishula Therapeutics. V.K.K. and A.C.A. are named inventors on patents related to TIM-3. K.O.D., V.K.K., M.T. and A.R. are named inventors on a provisional patent that has been filed including work from this study. A.R. and V.K.K. are co-founders of and have an ownership interest in Celsius Therapeutics. Additionally, A.R. is a co-founder and equity holder in Immunitas Therapeutics, and was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Asimov, and Neogene Therapeutics until 31 July 2020. A.C.A. is a member of the advisory board for Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zumutor Biologics and ImmuneOncia and is a paid consultant for Larkspur Biosciences and iTeos Therapeutics. A.R. and O.R.-R. are co-inventors on patent applications filed by the Broad Institute to inventions relating to single-cell genomics. The interests of V.K.K. were reviewed and managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict-of-interest policies. The interests of A.R. were reviewed and managed by the Broad Institute and HHMI in accordance with their conflict-of-interest policies. Since 1 August 2020, A.R. has been an employee of Genentech, a member of the Roche group. O.R.-R. is currently an employee of Genentech. The authors declare no other competing interests.